Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.
Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120